GGrantIndex
Sort

50,496 grants matching lung cancer

Impact of Cryptococcus Titan Cells on Pathogenesis.

$502,026
Kirsten Nielsen · University Of Minnesota · R01 · FY2021 · AI

Impact of Cryptococcus Titan Cells on Pathogenesis.

$502,026
Kirsten Nielsen · University Of Minnesota · R01 · FY2022 · AI

Impact of Cryptococcus Titan Cells on Pathogenesis.

$502,026
Kirsten Nielsen · University Of Minnesota · R01 · FY2019 · AI

Impact of Cryptococcus Titan Cells on Pathogenesis.

$502,026
Kirsten Nielsen · University Of Minnesota · R01 · FY2020 · AI

Training in Molecular & Genetic Epidemiology of Cancer

$502,022
John S Witte · University Of California, San Francisco · R25 · FY2007 · CA

Optimizing Personalized Screening and Diagnostic Decisions for Lung Cancer Based on Dynamic Risk Assessment and Life Expectancy

$502,013
Iakovos Toumazis · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA

IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy

$502,010
Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2024 · CA

miR-155 targeted therapeutics for precision medicine in lung cancer

$501,986
George A. Calin · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA

Computational Tools for Next Generation Volumetric Cone Beam Computed Tomography

$501,863
Lei Xing · Stanford University · R01 · FY2014 · EB

Metabolism of Carcinogenic Tobacco-Specific Nitrosamines

$501,839
Stephen S Hecht · University Of Minnesota · R37 · FY2011 · CA

Interpretable graphical models for large multi-modal COPD data (R01HL159805)

$501,802
Panagiotis V Benos · University Of Florida · R01 · FY2022 · HL

Nanoparticles-mediated combination therapy for breast cancer

$501,746
Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

Systematic Error and Confounding: Meta-Analyses of Alcohol and Disease

$501,598
Kaye M Fillmore · Scientific Analysis Corporation · R01 · FY2012 · AA

Quantitative Imaging to Assess Response in Cancer Therapy Trials

$501,587
John M Buatti · University Of Iowa · U01 · FY2014 · CA

The role of neutral ceramidase in acute kidney injury and its progression to chronic kidney disease.

$501,565
Leah J Siskind · University Of Louisville · R01 · FY2020 · DK

The role of neutral ceramidase in acute kidney injury and its progression to chronic kidney disease.

$501,565
Leah J Siskind · University Of Louisville · R01 · FY2021 · DK

Contribution of development and age to breast cancer etiology

$501,556
Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2017 · CA

Roles of p63 in regulation of miRNA and LincRNA targets in metastatic cancer

$501,539
Elsa R Flores · University Of Tx Md Anderson Can Ctr · R01 · FY2012 · CA

NAPTA: Optimizing clinical trial design & delivery of particle therapy for cancer

$501,487
Mack Roach · University Of California, San Francisco · P20 · FY2015 · CA

Project 2: Functional Genetic Networks for Systems-Guided Precision Medicine

$501,398
Stephanie Irene Fraley · University Of California, San Francisco · U54 · FY2023 · CA

Risk Factors for Sepsis in the Community

$501,341
Henry E Wang · University Of Alabama At Birmingham · R01 · FY2014 · NR

Outcomes of Triaged Family Care in Advanced Cancer

$501,336
Laurel L. Northouse · University Of Michigan At Ann Arbor · R01 · FY2006 · CA

Tumor cell metabolism in action

$501,299
Eileen White · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA

Leadership, Planning, and Evaluation

$501,296
Kelvin P Lee · Indiana University Indianapolis · P30 · FY2020 · CA

Leadership, Planning, and Evaluation

$501,296
Patrick J Loehrer · Indiana University Indianapolis · P30 · FY2022 · CA